Product Revenue Reserves and Allowances - Additional Information (Detail) - USD ($) $ in Thousands			3 Months Ended	12 Months Ended
	May 17, 2024	Apr. 18, 2024	Dec. 31, 2024	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue					$ 43,273	$ 46,018
Issuance of stock, net of issue costs, shares		2,180,776
ANI Pharmaceuticals, Inc. [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Product rights agreement, closing date					May 17, 2023
Receipt of upfront license fee					$ 75,000
Eyebiotech License Agreement [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Upfront cash payment	$ 500
Receipt of upfront license fee					500
Product Sales License and Collaboration Revenue or Royalty Income [Member] | Exclusive License Agreement With Betta Pharmaceuticals Company Limited [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue					0	0
Royalty Income [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue					1,613	989
Royalty Income [Member] | Ocumension Therapeutics [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue					500	0
RPA [Member] | SWK [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Upfront cash payment					16,500
Deferred revenue, current			$ 1,800		1,800	1,400
Deferred revenue, non-current			10,900		10,900	12,400
Revenue					1,100	1,000
YUTIQ [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue					$ 3,100	14,200
Supply Agreement [Member] | ANI Pharmaceuticals, Inc. [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Initial term of the supply agreement					2 years
Initial Term of Estimated Supply Units					2 years
License and Collaboration Agreement [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue					$ 38,496	30,797
License and Collaboration Agreement [Member] | Ocumension Therapeutics [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue					100	100
License and Collaboration Agreement [Member] | ANI Pharmaceuticals, Inc. [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue					700	1,000
License and Collaboration Agreement [Member] | Eyebiotech License Agreement [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue					500
Product Rights Agreement [Member] | ANI Pharmaceuticals, Inc. [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Upfront cash payment					75,000
Guaranteed payments			1,875		7,500
Deferred revenue, current			15,900		15,900
Deferred revenue, non-current			$ 0		$ 0
Product Rights Agreement [Member] | ANI Pharmaceuticals, Inc. [Member] | Maximum [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Royalties payment period					2028
Product Rights Agreement [Member] | ANI Pharmaceuticals, Inc. [Member] | Minimum [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Royalties payment period					2025
Product Rights Agreement [Member] | Product Rights Agreement and the Supply Agreement [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue					$ 37,100	29,500
Product Rights Agreement [Member] | Forecast [Member] | ANI Pharmaceuticals, Inc. [Member] | Maximum [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Royalty payments				$ 70,000
Product [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue					3,164	14,232
Product [Member] | Ocumension Therapeutics [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue					500	500
Product [Member] | Product Rights Agreement and the Supply Agreement [Member]
Disclosure of Product Revenue Reserves and Allowances [Line Items]
Revenue					$ 2,600	$ 2,100